


Lysander-Patient Capital Equity Fund

Six-Month Period Ended June 30, 2026

Interim Financial Statements

Unaudited



THE AUDITORS OF THE FUND HAVE NOT REVIEWED THESE FINANCIAL STATEMENTS.

Lysander Funds Limited, the Manager of the Fund, appoints an independent auditor to audit the Fund's annual financial statements. Applicable securities laws require that if an auditor has not reviewed the Fund's interim financial statements, this must be disclosed in an accompanying notice. The next report on the Fund will contain annual audited financial information as at December 31, 2026.

Table of Contents

Interim Financial Statements

Interim Statements of Financial Position	1
Interim Statements of Comprehensive Income (Loss)	2
Interim Statements of Changes in Net Assets Attributable to Holders of Redeemable Units	3
Interim Statements of Cash Flows	5
Interim Schedule of Investment Portfolio	6
Notes to the Interim Financial Statements	7

Lysander-Patient Capital Equity Fund

Interim Statements of Financial Position (unaudited)

As at		June 30, 2026	December 31, 2025
Assets			
Financial assets at fair value through profit or loss*	\$	17,154,475	\$ 14,340,705
Cash and cash equivalents		1,848,809	4,911,612
Receivable from Manager		7,584	15,015
Accrued interest		7,539	19,923
Dividends receivable		79,338	69,561
Subscriptions receivable		3,000	-
Reimbursements receivable		7	4
Total assets	\$	19,100,752	\$ 19,356,820
Liabilities			
Accrued expenses	\$	22,025	\$ 32,821
Redemptions payable		3,000	-
Total liabilities	\$	25,025	\$ 32,821
Net assets attributable to holders of redeemable units	\$	19,075,727	\$ 19,323,999
Net assets attributable to holders of redeemable units, per series			
Series A	\$	1,462,398	\$ 1,302,146
Series F		17,613,329	18,021,853
Total net assets	\$	19,075,727	\$ 19,323,999
Number of redeemable units outstanding			
Series A		89,158	88,242
Series F		1,118,889	1,271,412
Net assets attributable to holders of redeemable units per unit			
Series A	\$	16.40	\$ 14.76
Series F		15.74	14.17
* Financial assets at fair value through profit or loss at cost	\$	12,884,197	\$ 11,580,727

Lysander-Patient Capital Equity Fund

Interim Statements of Comprehensive Income (Loss) (unaudited)

For the periods ended		June 30, 2026	June 30, 2025
Income			
Interest for distribution purposes	\$	31,357	\$ 78,626
Dividend income		374,903	291,510
Other income		6,148	6,055
Realized and unrealized gain (loss) on investments			
Net realized gain (loss) on investments sold		522,424	172,264
Net realized gain (loss) on foreign currency		(399)	(642)
Change in unrealized appreciation (depreciation) on foreign currency		1	-
Change in unrealized appreciation (depreciation) on investments		1,513,022	388,795
Total operating income (loss)	\$	2,447,456	\$ 936,608
Expenses			
Management fees	\$	91,323	\$ 76,349
Filing fees		6,875	11,302
Fund administration fees		4,498	3,415
Transaction costs		2,722	379
Custodial fees		2,641	2,308
Unitholder reporting expense		862	393
Audit fees expense		624	393
Independent review committee fees		462	393
Legal fees expense		462	393
Regulatory fees expense		462	393
Total operating expenses	\$	110,931	\$ 95,718
Withholding tax	\$	7,737	\$ 4,013
Expense reimbursement	\$	(7,584)	\$ (11,121)
Total net operating expenses	\$	111,084	\$ 88,610
Change in net assets attributable to holders of redeemable units from operations	\$	2,336,372	\$ 847,998
Change in net assets attributable to holders of redeemable units from operations per Series			
Series A	\$	161,015	\$ 45,360
Series F		2,175,357	802,638
Change in total net assets	\$	2,336,372	\$ 847,998
Change in net assets attributable to holders of redeemable units from operations per unit			
Series A	\$	1.82	\$ 0.62
Series F		1.89	0.67

Lysander-Patient Capital Equity Fund

Interim Statements of Changes in Net Assets Attributable to Holders of Redeemable Units (unaudited)

For the periods ended		June 30, 2026	June 30, 2025
Net assets attributable to holders of redeemable units, beginning of period	\$	19,323,999	\$ 15,339,312
Change in net assets attributable to holders of redeemable units from operations		2,336,372	847,998
Distributions to unitholders of redeemable units			
From net investment income		(292,832)	(300,878)
From management fee rebate income		(5,992)	(6,055)
Total distributions	\$	(298,824)	\$ (306,933)
Redeemable unit transactions			
Proceeds from redeemable units issued			
Series A	\$	112,080	\$ 109,690
Series F		1,457,855	1,006,651
Total proceeds	\$	1,569,935	\$ 1,116,341
Cost of units redeemed			
Series A		(112,843)	(61,329)
Series F		(3,884,022)	(433,442)
Total cost	\$	(3,996,865)	\$ (494,771)
Reinvested distributions			
Series A		14,048	12,936
Series F		127,062	166,117
Total reinvested	\$	141,110	\$ 179,053
Change in net assets attributable to holders of redeemable units for the period	\$	(248,272)	\$ 1,341,688
Net assets attributable to holders of redeemable units, end of period	\$	19,075,727	\$ 16,681,000

Series A

For the periods ended		June 30, 2026	June 30, 2025
Net assets attributable to holders of redeemable units, beginning of period	\$	1,302,146	\$ 904,177
Change in net assets attributable to holders of redeemable units from operations		161,015	45,360
Distributions to unitholders of redeemable units			
From net investment income		(14,048)	(12,936)
Total distributions	\$	(14,048)	\$ (12,936)
Redeemable unit transactions			
Proceeds from redeemable units issued		112,080	109,690
Cost of units redeemed		(112,843)	(61,329)
Reinvested distributions		14,048	12,936
Total redeemable	\$	13,285	\$ 61,297
Change in net assets attributable to holders of redeemable units for the period	\$	160,252	\$ 93,721
Net assets attributable to holders of redeemable units, end of period	\$	1,462,398	\$ 997,898

Lysander-Patient Capital Equity Fund

Interim Statements of Changes in Net Assets Attributable to Holders of Redeemable Units (unaudited) (cont'd)

Series F

For the periods ended	June 30, 2026	June 30, 2025
Net assets attributable to holders of redeemable units, beginning of period	\$ 18,021,853	\$ 14,435,135
Change in net assets attributable to holders of redeemable units from operations	2,175,357	802,638
Distributions to unitholders of redeemable units		
From net investment income	(278,784)	(287,942)
From management fee rebate income	(5,992)	(6,055)
Total distributions	\$ (284,776)	\$ (293,997)
Redeemable unit transactions		
Proceeds from redeemable units issued	1,457,855	1,006,651
Cost of units redeemed	(3,884,022)	(433,442)
Reinvested distributions	127,062	166,117
Total redeemable	\$ (2,299,105)	\$ 739,326
Change in net assets attributable to holders of redeemable units for the period	\$ (408,524)	\$ 1,247,967
Net assets attributable to holders of redeemable units, end of period	\$ 17,613,329	\$ 15,683,102

Lysander-Patient Capital Equity Fund

Interim Statements of Cash Flows (unaudited)

For the periods ended	June 30, 2026	June 30, 2025
Cash flows from (used in) operating activities		
Change in net assets attributable to holders of redeemable units from operations	\$ 2,336,372	\$ 847,998
Adjustments for:		
Net realized loss (gain) on sales of investments	(522,424)	(172,264)
Change in unrealized depreciation (appreciation) on investments	(1,510,300)	(388,416)
Change in unrealized depreciation (appreciation) on foreign currency	(1)	-
Purchase of investments	(3,132,218)	(784,150)
Proceeds from sale and maturity of investments	2,351,172	518,368
Accrued expenses	(10,796)	(5,809)
Receivable from Manager	7,431	11,263
Reimbursements receivable	(3)	-
Dividends receivable	(9,777)	7,009
Accrued interest	12,384	9,048
Net cash from (used in) operating activities	\$ (478,160)	\$ 43,047
Cash flows from (used in) financing activities		
Distributions paid to holders of redeemable units, net of reinvested distributions	\$ (157,714)	\$ (127,880)
Proceeds from issuances of redeemable units	1,566,935	1,116,217
Amounts paid on redemption of redeemable units	(3,993,865)	(508,805)
Net cash from (used in) financing activities	\$ (2,584,644)	\$ 479,532
Foreign exchange gain (loss) on cash and cash equivalents	1	-
Change in cash and cash equivalents during the period	(3,062,804)	522,579
Cash, beginning of period	135,292	38,041
Cash equivalents, beginning of period	4,776,320	4,993,968
Cash, end of period	58,007	27,156
Cash equivalents, end of period	1,790,802	5,527,432
Cash and cash equivalents, end of period	\$ 1,848,809	\$ 5,554,588
Supplementary disclosures on cash flow from operating activities		
Interest received	\$ 43,740	\$ 87,674
Dividends received	365,127	298,519
Withholding tax	7,737	4,013

Lysander-Patient Capital Equity Fund

Interim Schedule of Investment Portfolio as at June 30, 2026 (unaudited)

	Par Value/Number of Shares	Average Cost \$	Fair Value \$
Canadian Equities (65.7%)			
Bank of Montreal	5,601	\$ 599,929	\$ 1,404,003
Bank of Nova Scotia	10,452	721,398	1,288,418
BCE Inc Com New	31,990	1,346,920	977,295
Canadian Imperial Bank of Commerce	8,605	517,781	1,405,369
Canadian Natural Resources	17,200	527,470	965,264
Cdn. Utilities Ltd.	27,285	887,484	1,438,465
Enghouse Systems Ltd.	65,125	1,120,311	1,045,908
Firm Capital Mortgage Investment Corp.	19,792	188,965	240,077
Linamar Corp	11,915	707,284	1,198,292
Telus Corp.	61,828	1,187,846	927,420
Toronto Dominion Bank	8,200	623,422	1,414,008
West Fraser Timber Co.	2,300	188,469	220,823
Total		\$ 8,617,279	\$ 12,525,342
Foreign Equities (19.0%)			
Adobe Systems Incorporated	645	181,992	187,718
Clorox Co.	7,060	970,757	956,499
Coca-Cola FEMSA	1,680	191,088	253,389
GENERAL MILLS INC.	18,325	1,003,434	905,258
Honda Motor Co. Ltd. ADR	22,660	808,006	872,046
Kenvue Inc.	16,850	370,938	457,099
Total		\$ 3,526,215	\$ 3,632,009
Income Trust (5.2%)			
Firm Capital Property Trust	142,650	740,703	997,124
Total		\$ 740,703	\$ 997,124
Zero Coupon Bonds (0.0%)			
Total investment portfolio (89.9%)		\$ 12,884,197	\$ 17,154,475
Cash and Cash Equivalents (9.7%)			1,848,809
Other Assets less Liabilities (0.4%)			72,443
Net assets			\$ 19,075,727

Lysander-Patient Capital Equity Fund

Notes to the Interim Financial Statements for the six-month period ended June 30, 2026 (unaudited)

1. Formation of Fund

The address of the Fund's registered office is 3080 Yonge St., Suite 4000, Toronto, Ontario.

Lysander Funds Limited (the "Manager" or "Lysander") is the manager and trustee of the Fund and is responsible for providing or arranging the provision of all general management and administrative services required by the Fund in its day-to-day operations, including but not limited to, calculating and reporting the net asset value of the Fund and its series, preparing all offering documents, unitholder recordkeeping and other administrative services.

Lysander-Patient Capital Equity Fund (the "Fund") is an open-end fund formed under the laws of the Province of Ontario by an amended and restated master declaration of trust dated as of November 26, 2025, as may be amended and/or restated from time to time. At the time it was formed, the Fund's name was "18 Asset Management All-Cap Canadian Equity Fund". On December 31, 2012, the Fund commenced operations and offered units pursuant to prospectus exemptions. On December 30, 2014, the Fund became a reporting issuer, with its units qualified for distribution under a simplified prospectus and changed its name to "Lysander-18 Asset Management Canadian Equity Fund". On November 1, 2021, the Fund further changed its name to "Lysander-Patient Capital Equity Fund".

The investment objective of the Fund is to provide long-term capital growth by investing primarily in equity securities anywhere in the world.

The portfolio manager of the Fund is Patient Capital Management Inc. ("Portfolio Manager").

2. Basis of Presentation

These interim financial statements (the "financial statements") have been prepared in compliance with IFRS Accounting Standards as issued by the International Accounting Standards Board ("IASB"). These financial statements have been prepared in accordance with IAS 34 Interim Financial Reporting and do not include all of the information and disclosures required in the annual financial statements. These financial statements should be read in conjunction with the Fund's annual financial statements and accompanying note disclosures.

The financial statements were authorized for issue by Lysander's board of directors on August 27, 2026.

3. Material Accounting Policy Information

The material accounting policies of the Fund are as follows:

Cash and cash equivalents

Cash and cash equivalents includes cash on hand, deposits held at call with banks, other short-term investments in an active market with original maturities of three months or less, bank overdrafts and money market funds with daily liquidity and all highly liquid financial instruments that mature within three months of being purchased.

Financial instruments

The Fund accounts for its financial instruments in accordance with IFRS 9 Financial Instruments ("IFRS 9"), which include cash and cash equivalents, investments at fair value through profit or loss, accrued interest, reimbursement receivable, subscriptions receivable, redemption payable, due to/from investment dealer, receivable/payable from forward exchange contracts and accrued expenses.

Financial assets and financial liabilities at fair value through profit or loss ("FVTPL")

Financial Assets

The Fund classifies its investments in debt and equity securities and open-ended investment funds based on its business model for managing those financial assets and the contractual cash flow characteristics of the financial assets.

These financial assets are managed and their performance is evaluated on a fair value basis. The Fund also manages these financial assets with the objective of realizing cash flows through sales. The Fund has not taken the option to irrevocably designate any of its equity securities at fair value through other comprehensive income ("FVOCI"). Consequently, these financial assets are mandatorily measured at FVTPL.

Lysander-Patient Capital Equity Fund

Notes to the Interim Financial Statements for the six-month period ended June 30, 2026 (unaudited) (cont'd)

3. Material Accounting Policy Information (continued):

Financial assets and financial liabilities at fair value through profit or loss ("FVTPL") (continued):

Financial Liabilities

Financial assets or financial liabilities held for trading are those acquired or incurred principally for the purpose of selling or repurchasing in the near future or on initial recognition are a part of a portfolio of identified financial instruments that the Fund manages together and has a recent actual pattern of short term profit-taking.

All derivatives and short positions are included in this category and mandatorily measured at FVTPL.

The Fund does not apply general hedge accounting to any of its derivatives positions.

Financial assets and financial liabilities at amortized cost

The financial assets and liabilities measured at amortized cost include cash collateral posted on derivative positions, accrued income, due to and from brokers and other short term receivables and payables.

IFRS 9 requires the expected credit loss model ("ECL") as the impairment model for financial assets measured at amortized cost. At each reporting date, the Fund measures the loss allowance on cash collateral held, amounts due from broker, accrued income and other short term receivables at an amount equal to the lifetime expected credit losses if the credit risk has increased significantly since initial recognition. If, at the reporting date, the credit risk has not increased significantly since initial recognition, the Fund measures the loss allowance at an amount equal to the 12 month expected credit losses. Given the short-term nature of the receivables and the high credit quality, the Fund has determined that the expected credit loss allowances are not material or considered impaired.

The Fund classifies financial instruments carried at fair value using a fair value hierarchy that reflects the significance of the inputs used in making the measurements.

- Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date;
- Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and
- Level 3 inputs are unobservable inputs for the asset or liability.

If an instrument classified as Level 1 subsequently ceases to be actively traded, it is transferred out of Level 1. In such cases, instruments are reclassified as Level 2, unless the measurement of its fair value requires the use of significant unobservable inputs, in which case it is reclassified as Level 3. The Manager assesses transfers at the time of an event that may cause reason for re-assessment of levelling. The classification within the hierarchy is based on the lowest level input that is significant to the fair value measurement. For this purpose, the significance of an input is assessed against the fair value measurement in its entirety. If a fair value measurement uses observable inputs that require significant adjustment based on unobservable inputs, that measurement is a Level 3 measurement. Assessing the significance of a particular input to the fair value measurement in its entirety requires judgment, considering factors specific to the asset or liability. The determination of what constitutes observable requires significant judgment by the Fund. The Fund considers observable data to be that market data that is readily available, regularly distributed or updated, reliable and verifiable, not proprietary, and provided by independent sources. The classification of the Fund's financial instruments within the fair value hierarchy as at June 30, 2026 and December 31, 2025, as applicable, is disclosed in the notes to the financial statements of the Fund. Significant transfers between levels are also disclosed in the notes to the financial statements of the Fund, where applicable. The reconciliation of Level 3 fair value measurements for the periods ended June 30, 2026 and December 31, 2025, if applicable, are included in the notes to the financial statements of the Fund.

Recognition/Derecognition

At initial recognition, financial assets and liabilities are measured at fair value. Transaction costs on financial assets and liabilities at fair value through profit or loss are expensed as incurred in the statement of comprehensive income (loss).

Subsequent to initial recognition, financial assets and liabilities at fair value through profit or loss are measured at fair value.

Gains and losses arising from changes in their fair value are included in the statement of comprehensive income (loss) for the period in which they arise. Dividend or interest income earned on financial assets at fair value through profit or loss and dividend or interest expense on the financial liabilities at fair value through profit or loss are disclosed in a separate line item in the statement of comprehensive income (loss).

Lysander-Patient Capital Equity Fund

Notes to the Interim Financial Statements for the six-month period ended June 30, 2026 (unaudited) (cont'd)

3. Material Accounting Policy Information (continued):

Recognition/Derecognition (continued):

Financial assets are derecognized when the contractual rights to the cash flows from the investments have expired or the Fund has transferred substantially all risks and rewards of ownership. Financial liabilities at fair value through profit or loss are derecognized when the obligation specified in the contract is discharged, cancelled or expired.

Investment transactions are accounted for on a trade date basis. Realized gains and losses on the disposition of investments, and unrealized appreciation and depreciation of investments, are determined on an average cost basis and are included in the statement of comprehensive income (loss).

Realized gains and losses related to options are included in net realized gain (loss) on options at fair value through profit or loss. Realized gains and losses relating to written options may arise from expiration of written options whereby realized gains are equivalent to the premium received and from the exercise of written covered call options in addition to the realized gains or losses from disposition of the related investments at the exercise price of the option.

Fair value measurements

The securities in the Fund's Portfolio are measured at FVTPL. The fair value of financial assets and liabilities traded in active markets are based on quoted market prices at the close of trading on the period-end date. The quoted market price used for financial assets and financial liabilities of the Fund is the last traded price provided such price is within the bid-ask spread. In circumstances where the last traded price is not within the bid-ask spread, the Fund will determine the points within the bid-ask spread that are most representative of the fair value. A financial instrument is regarded as quoted in an active market if quoted prices are readily and regularly available from an exchange, dealer, broker, industry group, pricing service, or regulatory agency, and those prices represent actual and regularly occurring market transactions on an arm's length basis. The fair value of financial assets and liabilities that are not traded in an active market is determined using valuation techniques commonly used by market participants making the maximum use of observable inputs and relying as little as possible on unobservable inputs. The Fund uses a variety of methods and makes assumptions that are based on market conditions existing at each reporting date.

Where available, valuation techniques use market observable assumptions and inputs. If such data is not available, inputs may be derived by reference to similar assets in active markets, from recent prices for comparable transactions or from other observable market data. When measuring fair value, the Fund selects the non-market-observable inputs to be used in its valuation techniques, based on a combination of historical experience, derivation of input levels based on similar products with observable price levels and knowledge of current market conditions and valuation approaches. Unobservable inputs are used to measure fair value to the extent that relevant observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date. However, the fair value measurement objective remains the same, i.e., an exit price at the measurement date from the perspective of a market participant that holds the asset or owes the liability. Therefore, unobservable inputs reflect the assumptions that market participants would use when pricing the asset or liability, including assumptions about risk. The output of a model is always an estimate or approximation of a value that cannot be determined with certainty, and valuation techniques employed may not fully reflect all factors relevant to the positions the Fund holds. Valuations are therefore adjusted, where appropriate, to allow for additional factors including model risk, liquidity risk and counterparty risk. Unlisted debt securities are valued based on observable inputs such as the prices provided by an independent reputable pricing services company who prices the securities based on recent transactions and quotes received from market participants and through incorporating observable market data and using standard market convention practices. Unlisted debt securities for which current quotations are not readily available are valued using another valuation technique as described below.

Lysander-Patient Capital Equity Fund

Notes to the Interim Financial Statements for the six-month period ended June 30, 2026 (unaudited) (cont'd)

3. Material Accounting Policy Information (continued):

Fair value measurements (continued):

The Fund uses widely recognized valuation techniques for determining the fair value of financial instruments that are not actively traded and quoted. The most frequently applied valuation techniques include: i) discounted value of expected cash flows, ii) relative value, iii) option pricing methodologies, iv) private placement financing technique, v) internally developed models and vi) market activity. In some cases, it may be reasonable and appropriate to value at cost, where there has been no material subsequent event affecting value. Discounted value of expected cash flows is a valuation technique that measures fair value using estimated expected future cash flows from assets or liabilities and then discounts these cash flows using a discount rate or discount margin that reflects the credit and/or funding spreads required by the market for instruments with similar risk and liquidity profiles to produce a present value. When using such valuation techniques, expected future cash flows are estimated using an observed or implied market price for the future cash flows or by using industry standard cash flow projection models. The discount factors within the calculation are generated using industry standard yield curve modeling techniques and models. Relative value models measure fair value based on the market prices of equivalent or comparable assets or liabilities, making adjustments for differences between the characteristics of the observed instrument and the instrument being valued. Option pricing models incorporate assumptions regarding the behavior of future price movements of an underlying referenced asset or assets to generate a probability-weighted future expected payoff for the option. The resulting probability-weighted expected payoff is then discounted using discount factors generated from industry standard yield curve modeling techniques and models. The option pricing model may be implemented using a closed form analytical formula or other mathematical techniques (e.g., binomial tree or Monte Carlo simulation). For more complex instruments and instruments for which there is no active market, fair values may be estimated using a combination of observed transaction prices, if any, consensus pricing services and relevant broker quotes. Consideration is given to the nature of the quotes (e.g., indicative or firm) and the relationship of recently evidenced market activity to the prices provided by consensus pricing services. Private placement financings are instances where a company raises capital through an offering of additional securities in the private markets. Pertinent details of such offering, including the terms of such offering, the issue price, and total capital raised are considered when assessing the reasonability that the issue price of such offering approximates fair value. In contrast to public offerings on a recognized exchange, private placement financings are not available to the general public. The Fund also uses internally developed models, which are typically based on valuation methods and techniques recognized as standard within the industry. Assumptions and inputs used in valuation techniques include benchmark interest rate curves, credit and funding spreads used in estimating discount rates, bond and equity prices, equity index prices, foreign exchange rates, levels of market volatility and correlation. In situations where there is limited market activity for the asset or liability near the measurement date, the most recent transaction price may be used.

Income recognition

Dividend income is recognized when the Fund's right to receive the payment has been established, normally being the ex-dividend date. Dividend income is recognized gross of withholding tax, if any.

The interest income for distribution purposes shown on the statement of comprehensive income (loss) represents the coupon interest received by the Fund accounted for on an accrual basis. The Fund does not amortize premiums paid or discounts received on the purchase of fixed income securities except for zero coupon bonds which are amortized on a straight line basis. The interest income for distribution purposes is the tax basis of calculating the interest received and which is subject to tax.

Offsetting financial instruments

Financial assets and liabilities are offset and the net amount reported in the statement of financial position when there is a legally enforceable right to offset the recognized amounts and there is an intention to settle on a net basis, or to realize the asset and settle the liability simultaneously.

Accounting estimates

In the application of the Fund's accounting policies, the Fund is required to make judgments, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily available from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered relevant. The most significant estimates relate to the valuation of investments. Actual results could differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods, if the revision affects both current and future periods.

Lysander-Patient Capital Equity Fund

Notes to the Interim Financial Statements for the six-month period ended June 30, 2026 (unaudited) (cont'd)

3. Material Accounting Policy Information (continued):

Net assets attributable to holders of redeemable units

Units issued and outstanding represent the capital of the Fund, with units in each series representing an equal and rateable share in the assets allocated to each series. The management fee rates are different for each of the series. Please refer to Note 6 for discussion of management fee rates. The redeemable units are classified as financial liabilities and are measured at the redemption amounts.

Units of the Fund may be purchased or redeemed at a price per unit equal to the net asset value ("NAV") of a unit of the applicable series of the Fund on each valuation date.

Net asset value per unit

The net asset value per unit of each series of units of the Fund is computed by dividing the NAV of a series of units by the total number of units of the series outstanding at the time. The Fund's accounting policies for measuring the fair value of its investments and derivatives are identical to those used in measuring its NAV for transactions with holders of redeemable units.

Foreign currency translation

Foreign currency amounts are translated into the Fund's functional currency as follows: fair value of investments, forward currency contracts and other financial assets and liabilities, at the closing rate of exchange on each business day; income and expenses, and purchases, sales and settlements of investments, at the rate of exchange prevailing on the respective dates of such transactions.

Foreign currency forward contracts

The value of the foreign currency forward contracts is the gain or loss that would be realized if the position in the forward contract was closed out in accordance with its terms. The unrealized gains or losses on the forward contract are reported as part of the change in unrealized appreciation or depreciation on forwards in the statement of comprehensive income (loss). Foreign currency forward contracts manage exposure to foreign currency gains and losses arising from short and long-term investments denominated in foreign currencies.

Taxation

The Fund is a mutual fund trust within the meaning of the Income Tax Act (Canada). The Fund is subject to tax on its net taxable income, including net realized capital gains, for the calendar year which is not paid or payable to its unitholders as of the end of the calendar year. It is the intention of the Fund to pay all of its net taxable income and net realized capital gains so that the Fund will not be subject to income taxes other than foreign withholding taxes, if applicable. Therefore, no provision for income taxes has been made in these financial statements.

As at December 31, 2025, the Fund had no net capital losses (December 31, 2024 - Nil) and no non-capital losses (December 31, 2024 - Nil).

Distributions

The Fund makes distributions of net income quarterly and any net realized capital gains annually. These are recognized in the statement of changes in net assets attributable to holders of redeemable units.

Significant accounting estimates and judgments

The preparation of financial statements requires management to use judgment in applying its accounting policies and to make estimates and assumptions about the future. The following discusses the most significant accounting judgments and estimates that the Fund has made in preparing the financial statements:

Determination of Functional Currency

'Functional currency' is the currency of the primary economic environment in which the Fund operates. If indicators of the primary economic environment are mixed, then the Fund uses its judgment to determine the functional currency that most faithfully represents the economic effect of the underlying transactions, events, and conditions. The Fund's subscriptions and redemptions are denominated in Canadian Dollars ("CAD"). Accordingly, the Fund has determined that the functional currency of the Fund is CAD unless noted otherwise.

Fair Value Measurement of Derivatives and Securities Not Quoted in an Active Market

The accompanying notes form an integral part of the interim financial statements.

Lysander-Patient Capital Equity Fund

Notes to the Interim Financial Statements for the six-month period ended June 30, 2026 (unaudited) (cont'd)

3. Material Accounting Policy Information (continued):

Significant accounting estimates and judgments (continued):

The Fund may hold financial instruments that are not quoted in active markets, including derivatives. Fair values of such instruments are determined as disclosed in Fair Value Measurement section in Note 3.

New accounting standards and Future changes in accounting standards

Presentation and Disclosure in Financial Statements

In April 2024, the IASB issued the new standard IFRS 18 – Presentation and Disclosure in Financial Statements that will replace IAS 1 – Presentation of Financial Statements. The new standard introduces newly defined subtotals on the income statement, requirements for aggregation and disaggregation of information, and disclosure of Management Performance Measures (“MPMs”) in the financial statements. The new standard is effective for annual reporting periods beginning on or after January 1, 2027, with early adoption permitted. The Fund is assessing the impacts to the financial statements.

4. Expenses

The Fund is responsible for the payment of all expenses related to its operations, including but not limited to audit fees, Independent Review Committee fees, fund administration fees, filing fees, redeemable unitholder reporting and custodian fees plus harmonized sales tax. At their discretion, the Manager or the Portfolio Manager may pay certain of the expenses of the Fund but any such payments shall not oblige the Manager or the Portfolio Manager to make similar future payments. All expenses are recognized in the statement of comprehensive income (loss) on the accrual basis.

Service fees may be paid by the Manager from the management fees it receives from the Fund. Service fees may be paid to brokers and dealers to compensate them for providing ongoing services to redeemable unitholders holding Series A units, if applicable.

The maximum service fee is 1.00% per annum on the Series A units, exclusive of any applicable taxes.

5. Issuance and Redemption of Units

The Fund is authorized to issue an unlimited number of transferable, redeemable units of beneficial interest, each of which represents an equal undivided interest in the net assets of the Fund. Each unit entitles the holder to the same rights and obligations as a holder of any other unit and no holder of units is entitled to any privilege, priority or preference in relation to any other holder of units. Each holder of units is entitled to one vote for each whole unit held and is entitled to participate equally with respect to any and all distributions made by the Fund, including distributions of net income and net realized capital gains, if any. On termination or liquidation of the Fund, the holders of outstanding units of record are entitled to receive on a pro rata basis all of the assets of the Fund remaining after payment of all debts, liabilities and liquidation expenses of the Fund. The units of the Fund are issued and redeemed at their NAV.

During the periods ended June 30, 2026 and 2025, the number of units issued, redeemed and outstanding were as follows:

Series A

For the periods ended	30-Jun-26	30-Jun-25
Units outstanding at beginning of period	88,242	68,908
Redeemable units issued	7,183	8,296
Redeemable units redeemed	(7,160)	(4,644)
Redeemable units issued on reinvestments	893	975
Units outstanding at end of period	89,158	73,535

Lysander-Patient Capital Equity Fund

Notes to the Interim Financial Statements for the six-month period ended June 30, 2026 (unaudited) (cont'd)

5. Issuance and Redemption of Units (continued):

Series F

For the periods ended	30-Jun-26	30-Jun-25
Units outstanding at beginning of period	1,271,412	1,143,596
Redeemable units issued	98,341	78,822
Redeemable units redeemed	(259,330)	(34,071)
Redeemable units issued on reinvestments	8,466	13,029
Units outstanding at end of period	1,118,889	1,201,376

6. Related Party Transactions

The Manager is responsible for the day-to-day management of the Fund and its investment portfolio in compliance with the Fund's constating documents. The Manager pays for the investment management services and provides all administrative services required by the Fund. As compensation for its services the Manager is entitled to receive a management fee.

The Manager may offer a reduced management fee to selected investors who (among other considerations) hold large investments in the Fund. This is achieved by reducing the management fee charged to the Fund based on the assets held by such investors and the Fund distributing the amount of the reduction in additional units of the same series of the Fund to the investor.

At June 30, 2026, the Manager, the majority shareholder of the Manager, the Manager's directors and officers together with certain immediate family members had an ownership interest in the Fund amounting to 24.0% (December 31, 2025 - 37.4%).

The Manager is entitled to receive from the Fund a management fee which is calculated daily and payable monthly at an annualized rate of up to 1.80% on Series A units, and up to 0.80% on Series F units, exclusive of applicable taxes, based on the net asset value of each respective series.

During the period ended June 30, 2026, the Manager paid the Portfolio Manager, \$36,964 (June 30, 2025 - \$31,439) for managing the portfolio of the Fund. As at June 30, 2026 the amount payable to the Portfolio Manager was \$18,310 (December 31, 2025 - \$19,005).

7. Fair Value Hierarchy

The following fair value hierarchy table presents information about the Fund's assets measured at fair value, as described in Note 3, as at June 30, 2026 and December 31, 2025:

As at June 30, 2026	Level 1	Level 2	Level 3	Total
Financial Assets				
Equities	\$ 17,154,475	\$ -	\$ -	\$ 17,154,475
Total	\$ 17,154,475	\$ -	\$ -	\$ 17,154,475
As at December 31, 2025	Level 1	Level 2	Level 3	Total
Financial Assets				
Equities	\$ 14,340,705	\$ -	\$ -	\$ 14,340,705
Total	\$ 14,340,705	\$ -	\$ -	\$ 14,340,705

8. Risk Management

The Fund's activities expose it to a variety of financial risks in the normal course of operations. These include credit risk, liquidity risk, and market risk. The value of the investments in the Fund's portfolio can fluctuate as a result of changes in interest rates, general economic conditions, supply and demand conditions relating to specific securities, or news relating to a specific issuer. In order to manage risk, the Portfolio Manager will diversify the portfolio based on industry and credit rating category. Significant risks that are relevant to the Fund are discussed below.

Lysander-Patient Capital Equity Fund

Notes to the Interim Financial Statements for the six-month period ended June 30, 2026 (unaudited) (cont'd)

8. Risk Management (continued):

Credit risk

Credit risk is the risk of financial loss that could arise from a security issuer or counterparty to a financial instrument not being able to meet its financial obligations. The Fund's main exposure to credit risk consists of investments in debt instruments, such as bonds. The Fund is also exposed to counterparty risk from other assets, such as amounts due from investment dealer or subscriptions receivable. To manage this risk, the Portfolio Manager monitors the Fund's credit exposure and counterparty credit ratings.

The Fund measures credit risk and lifetime ECLs related to these trade receivables using historical analysis and forward looking information in determining the ECL.

As at June 30, 2026 and December 31, 2025, the Fund had no significant investments in debt instruments with credit ratings.

Liquidity risk

Liquidity risk is the risk that the Fund will encounter difficulty in meeting obligations, including any redemption of units for cash. The Fund is exposed to possible daily redemptions at the then current NAV per unit. Liquidity risk is managed by investing a significant portion of the Fund's assets in investments that are traded in an active market and that can be readily sold. All liabilities of the Fund are due within one year.

The following table presents the Fund's liabilities according to their maturity date as at June 30, 2026 and December 31, 2025:

As at June 30, 2026	Less Than One Month	1-3 Months	3 Months – 1 Year
Liquidity exposure			
Redemption Payable	\$ 3,000	\$ -	\$ -
Accrued expenses	-	22,025	-

As at December 31, 2025	Less Than One Month	1-3 Months	3 Months – 1 Year
Liquidity exposure			
Accrued expenses	\$ -	\$ 32,821	\$ -

Market risk

Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a fund asset will fluctuate because of changes in market interest rates. If applicable, to manage interest rate risk, the Portfolio Manager monitors exposures and maintains the portfolio duration within the limits specified in the investment policies and objectives of the Fund. If applicable, the Fund has calculated the sensitivity analysis below. Actual results may differ materially from this analysis.

The table below summarizes the Fund's exposure to interest rate risks based on the remaining term to maturity of the investments.

	Less than 1 year	1-5 years	More than 5 years
Interest rate exposure			
June 30, 2026	\$ 1,790,802	\$ -	\$ -
December 31, 2025	4,776,320	-	-

If interest rates had increased or decreased by 1% at June 30, 2026, with all other variables remaining constant, net assets of the Fund would have decreased or increased by approximately Nil (December 31, 2025- Nil).

Currency risk

The accompanying notes form an integral part of the interim financial statements.

Lysander-Patient Capital Equity Fund

Notes to the Interim Financial Statements for the six-month period ended June 30, 2026 (unaudited) (cont'd)

8. Risk Management (continued):

Market risk (continued):

Currency risk arises when the value of investments denominated in currencies other than CAD fluctuate due to changes in exchange rates. If applicable, the currency risk will typically be hedged by entering into foreign currency forward contracts, however some moderate currency exposure may be assumed if deemed to be beneficial to the Fund. If applicable, the Fund has calculated the sensitivity analysis below. Actual results may differ materially from this analysis.

The table below summarizes the Fund's net exposure (before hedging, if any) to currency risk as at:

Currency exposure	30-Jun-26 (%)	31-Dec-25 (%)
US Dollars	19.0	16.1

As at June 30, 2026, if the CAD had strengthened or weakened by 1% in relation to the above currencies, with all other factors remaining constant, the Fund's net assets would have decreased or increased by 0.2% (December 31, 2025 - 0.2%).

Price risk

Price risk is the risk that the value of financial instruments will fluctuate as a result of changes in market prices, whether caused by factors specific to an individual investment, its issuer or all factors affecting all instruments traded in a market or market segment. If applicable, this risk is managed through a careful selection of securities and other financial instruments within the parameters of the investment strategy and by maintaining a well-diversified portfolio. Exposure to price risk arises from investments in equity securities. If applicable, the Fund has calculated the sensitivity analysis below. Actual results may differ materially from this analysis.

As at June 30, 2026, approximately 89.9% (December 31, 2025 - 74.2%) of the Fund's net assets were invested in equity securities. If prices of these investments had increased or decreased by 5% as at June 30, 2026 with all other factors remaining constant, net assets would have increased or decreased, by approximately \$857,724 (December 31, 2025 - \$717,035).



Lysander-Patient Capital Equity Fund

3080 Yonge Street, Suite 4000
Toronto, ON M4N 3N1
www.lysanderfunds.com

® Lysander Funds is a registered trademark of Lysander Funds Limited